About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cost-Effectiveness of Medicare Drug Plans in Schizophrenia and Bipolar Disorder Examined

by Kathy Jones on February 22, 2013 at 7:45 PM
Font : A-A+

 Cost-Effectiveness of Medicare Drug Plans in Schizophrenia and Bipolar Disorder Examined

Generic drug coverage was cost-saving compared to no coverage in bipolar disorder and schizophrenia and also improved health outcomes in Medicare Part D, a new study published online today in the American Journal of Managed Care has found.

Researchers from the University of Pittsburgh School of Medicine, the Pitt Graduate School of Public Health, and Western Psychiatric Institute and Clinic of UPMC note that policymakers and insurers should consider generic-only coverage, rather than no gap coverage, to both conserve health care resources and improve health.

Advertisement

Medicare Part D offers prescription drug coverage for Medicare beneficiaries and since the program's inception in 2006, many enrollees have benefited from improved drug coverage and increased medication use. However, a major concern is the large coverage gap in the standard Part D design, where beneficiaries pay 100 percent of medication costs out-of-pocket. About one-third of all Medicare beneficiaries enter this coverage gap each year, and once there, they often reduce medication use, which may lead to increases in hospitalization and medical spending.

"This coverage gap is an even larger concern for Medicare beneficiaries with severe mental disorders such as bipolar and schizophrenia," said Kenneth J. Smith, M.D., M.S., associate professor of medicine and clinical and translational science at the University of Pittsburgh, and lead author of the study. "Our cost-effectiveness analysis of Part D plans is an unconventional yet instructive way to inform managed care decision-making."
Advertisement

Added concerns for mental health patients include:

  • Mental health patients are much more likely to enter the "gap:" 62 percent of Medicare beneficiaries with bipolar disorder and 56 percent of those with schizophrenia entered the gap in 2007.
  • If they discontinue psychotropic medications, they may relapse to more severe episodes and require psychiatric hospitalization.
  • They experience high rates of comorbid chronic physical conditions such as heart disease and diabetes, which can be exacerbated by untreated mental illness and increase morbidity, medical spending and mortality.

    The standard Part D benefit in 2007 included four phases: (1) an initial $265 deductible; (2) a period in which beneficiaries paid 25 percent of drug costs between $265 and $2,400; (3) a coverage gap in which they paid 100 percent of costs between $2,401 and $3,850, where they reached their total out-of-pocket spending catastrophic limit; and (4) a catastrophic coverage period where they paid 5 percent of costs.

    Although the standard Part D benefit includes these four phases, some companies offering Part D drug plans modified the design and offered either "actuarially equivalent" or enhanced plans. In 2007, for example, 72 percent of stand-alone Part D plans had the standard coverage gap, 27 percent offered coverage for generic drugs used in the gap, and fewer than 1 percent offered coverage for both brand-name and generic drugs.

    "Our objective was to examine differences in health outcomes and costs between coverage groups in patients with bipolar disorder and schizophrenia," added Smith. "We were most interested in differences between the no-gap and generic coverage groups because policies governing the plans' availability and affordability could affect health costs and outcomes for beneficiaries entering the coverage gap."

    Of the more than 180,000 patients with bipolar disorder and schizophrenia that were evaluated, 14.6 percent had no gap coverage, and 7.1 percent had generic coverage. The remainder had low-income subsidies with more generous coverage, and therefore, were not strictly comparable to the other two groups. When comparing the no-gap coverage and generic gap coverage groups, patients with generic coverage had better health outcomes and reduced total medical costs as follows:

    • In disabled recipients with bipolar disorder and no coverage, costs were $570 per person more than generic coverage ($25,090 annually for no gap coverage compared to $24,520 for generic coverage)
    • In an aged recipient with bipolar disorder and no coverage, costs were $563 more per year than generic coverage
    • In a disabled recipient with schizophrenia and no coverage, costs were $1,312 more per year than generic coverage
    • In an aged recipient with schizophrenia and no coverage, costs were $1,289 more per year than generic coverage

    Costs were lower with generic coverage due to fewer hospitalizations when this coverage was in place. The authors conclude that generic coverage in the gap is cost-saving compared with no-gap coverage (the standard part D design) and improves health outcomes.



    Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Schizophrenia Signature Drug Toxicity Quiz on Depression Bipolar Disorder What is Medicare / Medicaid? Loss of Taste Mental Health - Neurosis vs Psychosis Schizoaffective Disorder Mind-wandering 

Recommended Reading
Schizophrenia
Schizophrenia is a mental disorder characterized by symptoms of thought, behavior and social ......
Bipolar Disorder
Bipolar Disorder is a brain disorder in which people show “mood swings”. Changes in the level of ne...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Loss of Taste
Symptom of loss of taste usually occurs in combination with loss of smell and can be complete loss o...
Mental Health - Neurosis vs Psychosis
Mental well-being is a concern and abnormal coping of emotions can lead to neurosis or psychosis. Me...
Mind-wandering
Mind wandering is a spontaneous and unintentional shifting of attention of thoughts from a primary t...
Schizoaffective Disorder
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms that...
What is Medicare / Medicaid?
Medicaid / Medicare are different governmental programs that provide medical and health-related serv...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use